Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

  1. OncologyPRO
  2. Meeting Resources
  3. ESMO 2018 Congress

Should oligosymtomatic brain metastasis patients without oncogene addiction receive upfront systemic therapy?

Should oligosymtomatic brain metastasis patients without oncogene addiction receive upfront systemic therapy? - Pro

Date

21 Oct 2018

Session

Should oligosymtomatic brain metastasis patients without oncogene addiction receive upfront systemic therapy?

Topics

Tumour Site

Central Nervous System Malignancies

Presenters

Priscilla Brastianos

Authors

P. Brastianos

Author affiliations

  • Department Of Medicine, Massachusetts General Hospital, 2114 - Boston/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.